18F-Labelled probes for non-invasive assessment of the IDH genotype in glioma patients

Ziel/Aim Mutations of isocitrate dehydrogenase 1 (mIDH1) are frequent in diffuse gliomas (WHO grade 2–4) and distinguish these tumors from glioblastoma (WHO grade 4), so that they have gained importance for differential diagnosis and prognosis of glioma patients. While most current approaches for detection of mIDH1 require surgical tissue sampling, positron emission tomography (PET) with suitable radiolabelled probes could facilitate non-invasive prediction and longitudinal assessment of the IDH status. In the present study, a specific inhibitor[1] of mIDH1 was therefore chosen as the lead structure to prepare a 18F-labelled, mIDH1-selective PET tracer using copper mediated radiofluorination.